In a recent study mapping clonal evolution in adult patient-derived Ph+ ALL cells grown in immunodeficient mice, the loss of CDKN2A/B was associated with increased competitive advantage on a subclonal level, more aggressive growth in xenografts, a higher leukemia initiating frequency, and a trend toward inferior outcome in patients (80). This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.